Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Corix Bioscience's share price for the quarter that ended in Sep. 2017 was $1. Corix Bioscience's Shares Outstanding (EOP) for the quarter that ended in Sep. 2017 was 20.65 Mil. Therefore, Corix Bioscience's market cap for the quarter that ended in Sep. 2017 was $20.65 Mil.
Corix Bioscience's quarterly market cap
increased
from Mar. 2017 ($13.03 Mil) to Jun. 2017 ($19.19 Mil) and
increased
from Jun. 2017 ($19.19 Mil) to Sep. 2017 ($20.65 Mil).
Corix Bioscience's annual market cap
increased
from Jan. 2014 ($0.00 Mil) to Jan. 2015 ($2,146.00 Mil) but then
declined
from Jan. 2015 ($2,146.00 Mil) to Dec. 2016 ($9.58 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Corix Bioscience's Enterprise Value for Today is $0.00 Mil.
Corix Bioscience (OTCPK:CXBS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Corix Bioscience Market Cap Related Terms
Corix Bioscience Market Cap Historical Data
* Premium members only.
The historical data trend for Corix Bioscience's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Corix Bioscience's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corix Bioscience Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Corix Bioscience's Market Cap distribution charts can be found below:
* The bar in red indicates where Corix Bioscience's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Corix Bioscience's Market Cap for the fiscal year that ended in Dec. 2016 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corix Bioscience (CXBS) has a Market Cap of $0.00 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Corix Bioscience and its competitors.
Is Corix Bioscience's Market Cap too high?
Corix Bioscience's current Market Cap is $0.00 Mil.
How does Corix Bioscience's Market Cap compare to BKIT and YBAO?
Corix Bioscience's Market Cap of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. The industry median Market Cap is 204.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 204.29, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Corix Bioscience and its competitors. For the Drug Manufacturers industry, the median Market Cap is 204.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corix Bioscience's current Market Cap is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corix Bioscience stock overvalued right now?
Corix Bioscience (CXBS) has a current Market Cap of $0.00 Mil. The current Market Cap is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Corix Bioscience (CXBS), the current Market Cap is $0.00 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CXBS has been successfully added to your 